The Materiovigilance market is further divided by type into active monitoring, passive monitoring, real‑world evidence integration, signal detection, and root‑cause analysis. Active monitoring, which includes scheduled inspections and mandatory reporting protocols, commands the largest share—approximately 40 % of type‑related revenue—because regulators require systematic data capture for high‑risk devices. Passive monitoring relies on unsolicited adverse‑event submissions from clinicians and patients; it represents about 25 % of the market and is valued for its low‑cost data acquisition, though signal quality varies. Real‑world evidence integration, at 20 %, merges post‑market surveillance data with electronic health‑record streams, enabling longitudinal safety assessments and informing reimbursement decisions. Signal detection services, comprising 10 %, apply statistical algorithms to identify emerging safety trends across heterogeneous datasets. Finally, root‑cause analysis, the smallest segment at 5 %, provides forensic investigation of adverse events to support corrective‑action planning and regulatory filings. Together, these type‑based subsegments define the market taxonomy, allocating resources to software platforms, analytics expertise, and consultancy services in proportion to their risk‑mitigation impact.